HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Zanetti, Michela ^a   Zenti, Mariagrazia ^b   Barazzoni, Rocco ^a   Zardi, Federica ^b   Semolic, Annamaria ^a   Messa, Michele Giuseppe ^b   Mearelli, Filippo ^a   Russi, Gianpaolo ^c   Fonda, Maurizio ^a   Scarano, Luca ^c   Bonora, Enzo ^b   Cattin, Luigi ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PENTRAXIN 3; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; LOW DENSITY LIPOPROTEIN; SERUM AMYLOID P;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HELP LDL APHERESIS; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN APHERESIS SYSTEM; MALE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATIENT ASSESSMENT; PROTEIN BLOOD LEVEL; TREATMENT DURATION; APHERESIS; BLOOD; CONTROLLED CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

BLOOD COMPONENT REMOVAL; C-REACTIVE PROTEIN; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; SERUM AMYLOID P-COMPONENT;

EID: 84904267891     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101290     Document Type: Article

References (35)

1. Narverud I, Ueland T, Nenseter MS, Retterstøl K, Telle-Hansen VH, et al. (2011) Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor α system and interleukin-10. Atherosclerosis 214: 163-168.
2. Charakida M, Tousoulis D, Skoumas I, Pitsavos C, Vasiliadou C, et al. (2009) Inflammatory and thrombotic processes are associated with vascular dysfunction in children with familial hypercholesterolemia. Atherosclerosis 204: 532-7.
3. El Messal M, Beaudeux JL, Drissi A, Giral P, Chater R, et al. (2006) Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clin Chim Acta 366: 185-9. (Pubitemid 43330981)
4. Libby P, Lichtman AH, Hansson GK (2013) Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 38: 1092-1104.
5. Bondarenko S, Catapano AL, Norata GD (2014) The CD1d-Natural Killer T Cell Axis in Atherosclerosis. J Innate Immun 6: 3-12.
6. Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, et al. (2003) Characterization of the long pentraxin PTX3 as a TNF alpha-induced secreted protein of adipose cells. J Lipid Res 44: 994-1000. (Pubitemid 37279659)
7. Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, et al. (1997) Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-alpha and interleukin-1beta regulation. Biol Chem 272: 8172-8178. (Pubitemid 27147769)
8. Mantovani A, Valentino S, Gentile S, Inforzato A, Bottazzi B, et al. (2011) Pentraxins and atherosclerosis: the role of PTX3. The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules. Curr Pharm Des 17: 38-46.
9. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, et al. (2008) Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 215: 48-55. (Pubitemid 351619875)
10. Bosutti A, Grassi G, Zanetti M, Aleksova A, Zecchin M, et al. (2007) Relation between the plasma levels of LDL-cholesterol and the expression of the early marker of inflammation long pentraxin PTX3 and the stress response gene p66ShcA in pacemaker-implanted patients. Clin Exp Med 7: 16-23. (Pubitemid 46475004)
11. Ohbayashi H, Miyazawa C, Miyamoto K, Sagara M, Yamashita T, et al. (2009) Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb 16: 490-500.
12. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, et al. (2009) Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120: 699-708.
13. Leren TP, Berge KE (2011) Subjects with molecularly defined familial hypercholesterolemia or familial-defective apoB-100 are not being adequately treated. PLoS One Feb 18; 6: 616721, doi: 10.1371/journal.pone.0016721.
14. Hemphill LC (2010) Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresis. J Clin Lipidol 4: 346-349.
15. McGowan MP (2013) Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol - the role of LDL-apheresis. J Clin Lipidol 7: S21-S26.
16. Mellwig KP, Pulawski E, Horstkotte D, van Buuren F (2012) Lipid apheresis: oxidative stress, rheology, and vasodilatation. Clin Res Cardiol Suppl 7: S45-S49.
17. Hovland A, Lappegård KT, Mollnes TE (2012) LDL apheresis and inflammation-implications for atherosclerosis. Scand J Immunol 76: 229-236.
18. Cattin L, Petrucco A, Cazzolato G, Bon GB, Borelli V, et al. (1997) Low density lipoprotein-apheresis decreases oxidized low density lipoproteins and monocyte adhesion to endothelial cells. ASAIO J 43: 209-213. (Pubitemid 27209186)
19. Wang Y, Blessing F, Walli AK, Uberfuhr P, Fraunberger P, et al. (2004) Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 175: 145-150 (Pubitemid 38746921)
20. Banerjee S, Abu Fadel M, Sarode R, Terada L, Moritz T, et al. (2013) Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design. J Clin Apher Oct 4. doi: 10.1002/jca.21298.
21. van Buuren F, Kreickmann S, Horstkotte D, Kottmann T, Mellwig KP (2012) HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures. Clin Res Cardiol 7: 24-30.
22. Koga N (1999) The retardation of progression, stabilization, and regression of coronary and carotid atherosclerosis by low-density lipoprotein apheresis in patients with familial hypercholesterolemia. J Intern Med 246: 35-43.
23. Moriarty PM, Gibson CA, Shih J, Matias MS (2001) C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 158: 495-498. (Pubitemid 32913663)
24. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, et al. (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367: 1310-1320.
25. Iwata A, Miura S, Tanaka T, Ike A, Sugihara M, et al. (2012) Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin. Coron Artery Dis 23: 315-321.
26. Jylhävä J, Haarala A, Kähönen M, Lehtimäki T, Jula A, et al. (2011) Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol 164: 211-217.
27. Bambauer R, Bambauer C, Lehmann B, Latza R, Schiel R (2012) LDL-apheresis: technical and clinical aspects. Scientific World Journal 2012: 314283 doi: 10.1100/2012/314283.
28. Schaumann D, Welch-Wichary M, Voss A, Schmidt H, Olbricht CJ (1996) Prospective cross-over comparisons of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia. Eur J Clin Invest 26: 1033-1038. (Pubitemid 26386316)
29. Suzuki M, Yamane S, Matsugane T, Nobuto T, Azuma N, et al. (1996) Evaluation of double filtration plasmapheresis, thermofiltration, and low density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients. Artif Organs 20: 296-302. (Pubitemid 26174753)
30. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, et al. (2008) Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 28: 925-933.
31. Karakas MF, Buyukkaya E, Kurt M, Motor S, Akcay AB, et al. (2013) Serum pentraxin 3 levels are associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris. J Investig Med 61: 278-285.
32. Matsuzaki M, Hiramori K, Imaizumi T, Kitabatake A, Hishida H, et al. (2002) Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 40: 220-227. (Pubitemid 34756279)
33. Knoflach M, Kiechl S, Mantovani A, Cuccovillo I, Bottazzi B, et al. (2012) Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies. PLoS One;7:e31474. doi: 10.1371/journal.pone. 0031474.
34. Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, et al. (2009) Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 47: 471-477.
35. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, et al. (2004) prognostic significance oft he long pentraxin 3 PTX3 in acute myocardial infarction. Circulation 110: 2349-2354. (Pubitemid 39407338)